GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (STU:UP0) » Definitions » Cyclically Adjusted Book per Share

Ultragenyx Pharmaceutical (STU:UP0) Cyclically Adjusted Book per Share : €11.41 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Ultragenyx Pharmaceutical's adjusted book value per share for the three months ended in Mar. 2024 was €1.553. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €11.41 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Ultragenyx Pharmaceutical's average Cyclically Adjusted Book Growth Rate was 2.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-06), Ultragenyx Pharmaceutical's current stock price is €37.60. Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €11.41. Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio of today is 3.30.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ultragenyx Pharmaceutical was 7.39. The lowest was 2.68. And the median was 3.64.


Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 11.08 11.23

Ultragenyx Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.13 11.19 11.40 11.23 11.41

Competitive Comparison of Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio falls into.



Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ultragenyx Pharmaceutical's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.553/131.7762*131.7762
=1.553

Current CPI (Mar. 2024) = 131.7762.

Ultragenyx Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201406 3.748 100.560 4.911
201409 4.857 100.428 6.373
201412 4.697 99.070 6.248
201503 8.851 99.621 11.708
201506 7.886 100.684 10.321
201509 13.237 100.392 17.375
201512 12.539 99.792 16.558
201603 11.281 100.470 14.796
201606 10.118 101.688 13.112
201609 10.142 101.861 13.121
201612 10.895 101.863 14.094
201703 10.804 102.862 13.841
201706 9.008 103.349 11.486
201709 7.219 104.136 9.135
201712 7.336 104.011 9.294
201803 11.817 105.290 14.790
201806 12.024 106.317 14.903
201809 11.237 106.507 13.903
201812 10.523 105.998 13.082
201903 13.695 107.251 16.827
201906 12.581 108.070 15.341
201909 11.435 108.329 13.910
201912 10.173 108.420 12.364
202003 9.267 108.902 11.214
202006 10.224 108.767 12.387
202009 9.300 109.815 11.160
202012 14.201 109.897 17.028
202103 13.135 111.754 15.488
202106 11.907 114.631 13.688
202109 11.677 115.734 13.296
202112 11.774 117.630 13.190
202203 10.361 121.301 11.256
202206 9.162 125.017 9.657
202209 6.757 125.227 7.110
202212 4.740 125.222 4.988
202303 2.914 127.348 3.015
202306 1.666 128.729 1.705
202309 0.412 129.860 0.418
202312 3.068 129.419 3.124
202403 1.553 131.776 1.553

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Ultragenyx Pharmaceutical  (STU:UP0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=37.60/11.41
=3.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ultragenyx Pharmaceutical was 7.39. The lowest was 2.68. And the median was 3.64.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical (STU:UP0) Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (STU:UP0) Headlines

No Headlines